Circio Holding ASA Notice of annual general meeting 2026

Oslo, 17 April 2026: The annual general meeting of Circio Holding ASA (the "Company") will be held on Friday 8 May 2026 at 12:00 hours (CEST) as a physical meeting at the premises of Advokatfirmaet Thommessen AS, Ruseløkkveien 38, 0251 Oslo, Norway.

The notice and agenda of the annual general meeting is attached hereto, including further information on advance voting, power of attorney and physical participation. The notice and the nomination committees recommendation, and other documents referred to therein are made available on the Company's webpage www.circio.com under the heading "Investors".

For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com

Lubor Gaal, CFO Phone: +34 683 34 3811 Email: lubor.gaal@circio.com

About Circio Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.